TRVN:OTCMKTS
Trevena Inc
0,066 USD
0,00%
(0,00) 1 zi
12 oct., 14:57:26 GMT-4 · USD
search
Toate simbolurile
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru TRVN...
Capitalizarea bursieră
57,01 K
Volum mediu
210,00
Volum
23,00
Prețul ridicat pe 52 de săptămâni
1,50 USD
Prețul redus pe 52 de săptămâni
0,00 USD
Beta
1,07
Acțiuni aflate în circulație
864,00 K
Nr. de angajați
23
Capitalizarea bursieră
57,01 K
Volum mediu
210,00
Volum
23,00
Prețul ridicat pe 52 de săptămâni
1,50 USD
Prețul redus pe 52 de săptămâni
0,00 USD
Beta
1,07
Acțiuni aflate în circulație
864,00 K
Nr. de angajați
23
Subiecte de știri
Din surse web și de la parteneri de știri
ad-hoc-news.de
·
acum 12 ore
MarketBeat estimates results for Trevena stock
Profil
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Despre Trevena Inc
Director executiv-
Angajați23
Înființată la2007
SediuAtlanta, Georgia, Statele Unite ale Americii
Domeniu-
Sitetrevena.com